The inaugural Portfolio Strategy and Decision Making for Biopharma Summit is a must-attend event for leaders in the pharma and biotech industries who are aiming to refine their...

Liquid biopsies are revolutionizing clinical trials, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance....

With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical...

Welcome to the Cell and Gene Therapy Medical Affairs Summit! Delivering Impactful Education to Transform Patient Outcomes Introducing the Cell and Gene Therapy Medical Affairs...

CNS drug development is facing a new era, thanks to huge strides in neuroscience innovation, including advances in blood-brain barrier transport, CSF administration, and...

As supply issues with Ozempic persist for Novo Nordisk, and Eli Lilly launch an unconventional but affordable single-dose version of Zepbound; there has never been a more...

The landscape of internal medicine is evolving rapidly, presenting practicing clinicians with increasingly complex challenges to maintain cutting-edge patient care. In response...

With the applications of LNPs rapidly expanding beyond vaccines, as well as beyond the liver, it is of utmost importance to predict and minimize adverse reactions to guarantee...

In the face of unprecedented cost-per-patient expenses, the FDA's recent focus on rare disease, and a myriad of options for identifying, engaging, screening, and retaining...

With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an...

Uniting Large Pharma, Innovative Biotech and Leading Academics to Eliminate the Boundaries of Druggability with Novel Covalent Drugs With continued advancements in screening...

With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there has been many valuable collaborations entering the RNA-targeting field...

Achieving Efficacy and Exploring Indication Expansion for Complement Inhibitors The complement community is shifting gear, with more companies than ever targeting alternative...

Making Strides in Targeting PARP, ATR, ATM, WEE1 and POLθ AstraZeneca and Merck are at the forefront of DDR inhibitor development, focusing on next-generation PARP inhibitors...

Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical candidates. Just this year,...

The Protein Degradation for CNS Summit returns to Boston for its 2nd year running. With this ever-progressing field in neurodegenerative disease drug development, the design of...

The 3rd Viral Vector Process Development and Manufacturing Summit Enhancing Scale-Up, Increasing Quality, and Reducing Costs for AVs, LVVs, AAVs and More The 3rd Viral Vector...

Immune tolerance offers a transformative approach to autoimmune diseases treatment and holds the power to modify the course of disease progression and significantly improve the...

In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical. With the field anticipating finalized regulatory guidelines from the...

Updates, advances and practical information you can use now to screen, diagnose and manage patients with kidney disease With more than 50 interactive lectures and case-based...

Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to...

With Arbor Biotechnologies on-track for year-end IND/CTA filing of their LNP-mediated gene editing therapy and LNPs continuing to be the hottest delivery vehicle across all...